Stopping dangerous infections before they start: a new vaccine approach

Astrid Pérez

Instituto de Salud Carlos III, Madrid, Spain

This project is dedicated to creating a new kind of vaccine to prevent gut infections caused by Klebsiella pneumoniae, a harmful and difficult-to-treat bacteria. K. pneumoniae is a common cause of infections in hospitals, and it is becoming more and more resistant to the antibiotics we use today. As these bacteria get stronger, our traditional treatments are not working as well, so people—especially those who are already sick—are at greater risk of serious illness.

Unlike traditional vaccines that target infection, this vaccine focuses on stopping K. pneumoniae from settling in the intestine in the first place. Specifically, it exploits the bacteria’s own colonization strategy against it—like sabotaging an invader’s claws before they can scale the castle walls. By preventing the bacteria from attaching and growing in the intestines, the vaccine can help avoid illness and also stop the spread of germs to other people.

The vaccine is made using two smart ideas: i) repetitive structures that mimic the claws K. pneumoniae uses to attach to your colon. These “decoys” train the immune system to block the real bacteria before they can attach; ii) and tiny fat packages that act like microscopic delivery trucks, protecting the vaccine as it travels inside the body. These two parts work together to help the body build strong defences, both in the intestine and throughout the body, without needing extra chemicals.

By blocking K. pneumoniae before it causes problems, the vaccine helps keep people healthier and reduces the need to use antibiotics. This also slows down the rise of bacteria that no longer respond to usual treatments. The project’s approach is simple, can be adapted for other germs in the future, and is easy to produce. If this vaccine is successful, it could make hospital stays safer, protect the most vulnerable people, and become a powerful new tool in our efforts to fight germs like K. pneumoniae that put lives at risk worldwide.

A Nanovaccine-Based Immunotherapy Targeting Klebsiella pneumoniae Colonization

Stage 1